Condition: Cervical Cancer · Gynecologic Cancer · Recurrent Cancer · Sponsor: Tata Memorial Hospital
This is a prospective study to evaluate in-field disease control, survival and late toxicity in patients with cervical cancer or pelvic recurrence treated with spatially fractionated RT. The study will include patients with primary cervical cancer or pelvic recurrence not suitable for brachytherapy in view of anticipated or actual suboptimal target coverage due to aberrant anatomy or large residual disease at the time of brachytherapy.
This description comes directly from the study's public registry record.
Supriya Chopra, MD · 022-68735000 · supriyasastri@gmail.com
Ankita Gupta, MD · 9592750011 · ankita19.gupta.ag@gmail.com
Always discuss trial participation with your own doctor first.
| ACTREC Tata Memorial Centre | Navi Mumbai, Maharashtra, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06644846